67469-69-9|Vanoxerine|1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine|-范德生物科技公司

Vanoxerine

NMR下载 COA and HPLC MSDS下载
names：
1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine
CAS号：
67469-69-9
MDL Number：
MF(分子式)： C28H32F2N2O MW(分子量)： 450.56
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine
英文别名	Vanoxerine; GBR-12909; GBR12909; GBR 12909; I-893; I 893; I893.
CAS号	67469-69-9
SMILES	FC1=CC=C(C(C2=CC=C(F)C=C2)OCCN3CCN(CCCC4=CC=CC=C4)CC3)C=C1
Inchi	InChI=1S/C28H32F2N2O/c29-26-12-8-24(9-13-26)28(25-10-14-27(30)15-11-25)33-22-21-32-19-17-31(18-20-32)16-4-7-23-5-2-1-3-6-23/h1-3,5-6,8-15,28H,4,7,16-22H2
InchiKey	NAUWTFJOPJWYOT-UHFFFAOYSA-N
分子式 Formula	C28H32F2N2O
分子量 Molecular Weight	450.56
闪点 FP
熔点 Melting point
沸点 Boiling point
Polarizability极化度
密度 Density
蒸汽压 Vapor Pressure
溶解度Solubility
性状	Solid powder
储藏条件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

产品说明	Vanoxerine(CAS:67469-69-9 ):仅限应用于工业或者科学研究过程中非医疗目的，不应用于人类或动物的临床诊断以及治过程疗，该产品非药用，非食用。
Introduction	Vanoxerine, also known as GBR-12909; I-893, is a dopamine ruptake inhibitor potentially for the treatment of atrial fibrillation.
Application1
Application2
Application3

警示图
危险性	Warning
危险性警示
安全声明
安全防护
备注

[1]Cakulev I, Lacerda AE, Khrestian CM, Ryu K, Brown AM, Waldo AL. Oral vanoxerine prevents reinduction of atrial tachyarrhythmias: preliminary results. J Cardiovasc Electrophysiol. 2011 Nov;22(11):1266-73. doi: 10.1111/j.1540-8167.2011.02098.x. Epub 2011 May 26. PubMed PMID: 21615815; PubMed Central PMCID: PMC3172341.

[2]Matsumoto N, Khrestian CM, Ryu K, Lacerda AE, Brown AM, Waldo AL. Vanoxerine, a new drug for terminating atrial fibrillation and flutter. J Cardiovasc Electrophysiol. 2010 Mar;21(3):311-9. Epub 2009 Oct 8. PubMed PMID: 19817929.

[3] Lacerda AE, Kuryshev YA, Yan GX, Waldo AL, Brown AM. Vanoxerine: cellular mechanism of a new antiarrhythmic. J Cardiovasc Electrophysiol. 2010 Mar;21(3):301-10. Epub 2009 Oct 8. PubMed PMID: 19817928; PubMed Central PMCID: PMC3107714.

[4] Cherstniakova SA, Bi D, Fuller DR, Mojsiak JZ, Collins JM, Cantilena LR. Metabolism of vanoxerine, 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine, by human cytochrome P450 enzymes. Drug Metab Dispos. 2001 Sep;29(9):1216-20. PubMed PMID: 11502731.

[5] Preti A. Vanoxerine National Institute on Drug Abuse. Curr Opin Investig Drugs. 2000 Oct;1(2):241-51. PubMed PMID: 11249581.

6: Ingwersen SH, Snel S, Mant TG, Edwards D. Nonlinear multiple-dose pharmacokinetics of the dopamine reuptake inhibitor vanoxerine. J Pharm Sci. 1993 Nov;82(11):1164-6. PubMed PMID: 8289134.7: Ingwersen SH, Mant TG, Larsen JJ. Food intake increases the relative oral bioavailability of vanoxerine. Br J Clin Pharmacol. 1993 Mar;35(3):308-10. PubMed PMID: 8471409; PubMed Central PMCID: PMC1381581.8: Ingwersen SH. Column liquid chromatographic assay of the dopamine reuptake inhibitor vanoxerine (GBR 12909) in human serum. J Chromatogr. 1991 Nov 15;571(1-2):305-11. PubMed PMID: 1839795.

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开